Why Faeth Therapeutics, Inc.’s (FTH) Stock Is Up 6.08%
As of Wednesday, November 18, Faeth Therapeutics, Inc.’s FTH share price has surged by 6.08%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Tudor Pop
Jenna Brashear
Tudor Pop
Jenna Brashear
| Share Statistics | FTH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $225.4 | $213.9 | 30% |
|
| Shares Out (Mil) | 25.8 | 55.4 | 34% |
|
| Institutional Ownership | 93.2% | 93.3% | 62% |
|
| Float (Mil) | 16.9 | 40.6 | 26% |
|
| Beta | -0.18 | 0.98 | 3% |
|
| Avg Daily Volume (000s) | 1,130 | 597 | 71% |
|
| Price Change (52-week) |
7.1% | 40.9% | 57% |
|
| Growth | FTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (1.0%) | (10.7%) | 39% |
|
| EPS (5yr) | 41.8% | 15.5% | 90 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 3 | |
| Current EPS | ($0.880) | ($15.600) | ($3.670) | |
| Month Ago EPS | ($0.785) | ($9.973) | ($3.670) | |
| # Rev Up | 3 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.690) | ($11.980) | ($4.960) | |
| Year/Year Chg | 11.5% | (6.7%) | (77.0%) | |
| Financials | FTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($211) | ($44) | 6% |
|
| EPS (TTM) | ($24.641) | ($1.400) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($43) | ($34) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $-0 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $65 | $135 | 19% |
|
| Valuation | FTH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.40 | 1.97 | 42% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | FTH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (204.7%) | (47.5%) | 2% |
|
| ROE | (229.6%) | (51.9%) | 3% |
|
| Liabilities to Assets | 10.0% | 29.7% | 6% |
|
| F-Score | 3 | 3 | 18% |
|
Faeth Therapeutics, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors